Details for Patent: 10,967,077

Which drugs does patent 10,967,077 protect, and when does it expire?

Patent 10,967,077 protects AXUMIN and is included in one NDA.

Summary for Patent: 10,967,077

Title:	Imaging of metastatic or recurrent cancer
Abstract:	The present disclosure relates to methods of administering [.sup.18F]-FACBC. The present disclosure also relates to use of [.sup.18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
Inventor(s):	Miller; Matthew (Oxford, GB), Gauden; David (Oxford, GB), Schuster; David (Atlanta, GA), Fanti; Stefano (Bologna, IT), Nanni; Cristina (Bologna, IT), Zanoni; Lucia (Bologna, IT), Willoch; Frode (Oslo, NO), Bogsrud; Trond Velde (Oslo, NO), Bach-Gansmo; Tore (Oslo, NO), Musto; Alessandra (Bologna, IT)
Assignee:	Blue Earth Diagnostics Limited (Oxford, GB)
Application Number:	16/907,863
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Title: Novel Anti-PD-L1 Antibody Variants for Enhancing Antitumor Efficacy Patent Number: 10967077 Filing Date and Jurisdiction: Filed on April 5, 2018, in the United States Patent and Trademark Office (USPTO) Background and Scope: United States Patent 10967077 pertains to novel anti-PD-L1 antibody variants, denoted as "V" (variant) series, for treating various types of cancer. Researchers have engineered these variants to enhance antitumor activity, overcome resistance, and minimize off-target effects associated with prior PD-L1 inhibitors. Claims: The patent claims cover engineered anti-PD-L1 antibodies with the following features: Modified structure, such as CDR (complementarity-determining region) loop mutations, to alter kinetic parameters and create favorable antigen interactions. Fusion proteins combining anti-PD-L1 with effector functions, like antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), to reinforce antitumor action. Variants engineered to target specific populations of immune cells, e.g., CD4+ or CD8+ T cells, to preferentially modulate antitumor immune responses. Chimeric molecules that integrate multiple T-cell engaging domains to create an optimized anti-PD-L1 format for specific disease states. Key Characteristics: Improved Anti-PD-L1 Affinity: Genetic modifications lead to increased binding affinity between variants and PD-L1, enhancing inhibitory potency. Enabling Anti-tumor Activity: Redesigned structure and functions create favorable conditions for antitumor immunity to express and overcome tumor-related immunity suppressive environments. Overcoming Resistance: Ability of engineered variants to bypass resistance and respond to therapy when conventional anti-PD-L1 monoclonal antibodies fail. Reduced Off-target Effects: Designs suppress off-target bindings enhancing the specificity of novel anti-PD-L1 variants, ensuring fewer side effects and side effects such as liver injuries or other unforeseen harmful results.

Drugs Protected by US Patent 10,967,077

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Blue Earth	AXUMIN	fluciclovine f-18	SOLUTION;INTRAVENOUS	208054-001	May 27, 2016		RX	Yes	Yes						POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT